Enhertu

Enhertu. It is an antibody-drug conjugate used to treat certain types of HER2-positive and HER2-low breast cancer, as well as HER2-positive gastric cancer and non-small cell lung cancer. Developed through a collaboration between Daiichi Sankyo and AstraZeneca, it represents a significant advancement in targeted therapy for oncology.

Medical uses

Enhertu is approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior anti-HER2 regimens. It is also indicated for patients with HER2-low breast cancer, a novel classification. Additionally, it is used for HER2-positive metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after a prior trastuzumab-based regimen, and for HER2-mutant metastatic non-small cell lung cancer. Regulatory approvals have been granted by the U.S. Food and Drug Administration, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency.

Adverse effects

Common adverse reactions include nausea, fatigue, alopecia, vomiting, constipation, decreased appetite, anemia, and elevated levels of blood lactate dehydrogenase. The most serious and potentially life-threatening adverse effect is interstitial lung disease and pneumonitis, which requires vigilant monitoring and prompt intervention. Other significant risks include left ventricular dysfunction and embryo-fetal toxicity. Management often involves dose modifications, supportive care, and collaboration with specialists in cardiology and pulmonology.

Mechanism of action

Enhertu is a HER2-directed antibody-drug conjugate. The antibody component is a humanized anti-HER2 immunoglobulin G1, which binds with high affinity to the HER2 receptor on the surface of cancer cells. Upon binding and internalization, the stable linker is cleaved within the lysosome, releasing a potent topoisomerase I inhibitor payload. This payload causes DNA damage and apoptosis in the target cell and can also exert a potent bystander effect on neighboring tumor cells, which is a key feature of its efficacy against heterogeneous tumors.

History and development

The drug, initially known as DS-8201, was discovered and developed by the Japanese pharmaceutical company Daiichi Sankyo. A landmark global development and commercialization collaboration was formed with AstraZeneca in 2019. Its accelerated approval by the U.S. Food and Drug Administration for metastatic breast cancer was based on the groundbreaking DESTINY-Breast01 trial. Subsequent confirmatory trials, including DESTINY-Breast03, DESTINY-Breast04, DESTINY-Gastric01, and DESTINY-Lung02, led to expanded approvals across multiple cancer types and settings, transforming treatment paradigms.

Society and culture

Enhertu has been recognized as a breakthrough therapy, receiving multiple Breakthrough Therapy Designations from the U.S. Food and Drug Administration. Its development and clinical success have been widely covered in major medical journals like the New England Journal of Medicine and at conferences such as the American Society of Clinical Oncology annual meeting. The drug's high cost and access have been subjects of discussion within healthcare systems, including Medicare and private insurers. It has also been a focal point in the evolving narrative of precision medicine and biomarker-driven cancer care.

Category:Antineoplastic drugs Category:Monoclonal antibodies Category:AstraZeneca